Assessment of fracture risk based on FRAX score and Polish guidelines in patients with newly diagnosed osteoporosis
, 2, 1, 1
Abstract
Introduction: The authors of the latest recommendations state that osteoporosis diagnosis should not rely solely on densitometric (DXA) criteria. Fracture risk assessment is crucial for determining diagnosis and intervention thresholds. Comprehensive assessment of fracture risk requires consideration of bone mineral density (BMD) results, use of risk calculators like Fracture Risk Assessment Tool (FRAXTM), and analysis
of clinical and lifestyle factors. Experts highlight the need to identify patients at very high fracture risk to justify starting anabolic therapy. This retrospective study assessed fracture risk in newly diagnosed osteoporosis patients, identifying those at high and very high risk.
Material and methods: The study included 159 postmenopausal women with newly diagnosed osteoporosis, identified by a T-score of ≤ –2.5 standard deviations (SD) from DXA scans of the femoral neck and/or lumbar spine. Demographic data and laboratory tests were collected, and the 10-year fracture risk for major osteoporotic fractures (FRAX MOF) and hip fractures (FRAX HF) was calculated using the FRAX-PL calculator, which included femoral neck BMD. Each patient was then classified into a risk group based on modified fracture risk assessment criteria.
Results: The study found that the most common risk factor for osteoporosis was a previous fracture (56.6%). Other common risk factors included smoking (21.38%), parental hip fracture (13.21%), and glucocorticoid use (10.70%). The FRAX calculator showed that 47.80% of patients were at very high risk for HF and 23.90% for MOF. A high HF risk was present in 10.06% of patients, and high MOF risk in 34.59%, whereas a medium and low MOF risk concerned 25.79% and 15.72% of the subjects, respectively. With expanded criteria, 72.33% of patients were classified at very high risk, compared to 23.90% for MOF and 47.80% for HF based solely on FRAX. Most patients met the T-score ≤ –3.0 SD criterion (52.20%) and FRAX > 15% for MOF or FRAX > 4.5% for HF (52.20%). Women aged 65–70 and 70–75 years are at the highest risk and qualify for anabolic therapy.
Conclusions: Our study highlights the importance of stratifying patients by fracture risk, showing that more individuals are identified at very high risk when using the expanded assessment criteria from the latest Polish guidelines.
Keywords: fracture riskFRAXvery high risk for fracturesguidelinesosteoporosis
References
- Willers C, Norton N, Harvey NC, et al. SCOPE review panel of the IOF. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022; 17(1): 23.
- Narodowy Fundusz Zdrowia. Narodowy Fundusz Zdrowia. NFZ o Zdrowiu: Osteoporoza. Centrala Narodowego Funduszu Zdrowia, Departament Analiz i Strategii, Warszawa 2019.
- Narodowy Fundusz Zdrowia. NFZ o Zdrowiu: Osteoporoza. Centrala Narodowego Funduszu Zdrowia, Departament Analiz i Strategii, Warszawa 2023; Narodowy Fundusz Zdrowia: NFZ o zdrowiu. Osteoporoza. https://ezdrowie.gov.pl/portal/home/badania-i-dane/zdrowe-dane/raporty/nfz-o-zdrowiu-osteoporoza.
- Głuszko P, Sewerynek E, Misiorowski W, et al. Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2022. Endokrynol Pol. 2023; 74(1): 5–15.
- Głuszko P. Osteoporoza — postępy 2023/2024. Med Prakt. 2024; 4: 71–77.
- Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020; 31(1): 1–12.
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. Endocr Pract. 2020; 26(Suppl 1): 1–46.
- Miyauchi A, Hamaya E, Shimauchi J, et al. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. J Bone Miner Metab. 2024; 42(1): 77–89.
- Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018; 391(10117): 230–240.
- Saag KG, Petersen J, Grauer A, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017; 377(15): 1417–1427.
- FRAX ®Kalkulator ryzyka złamania. https://frax.shef.ac.uk/FRAX/tool.aspx?lang=po.
- McCloskey E, Rathi J, Heijmans S, et al. Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe. Arch Osteoporos. 2022; 17(1): 20.
- Johansson H, Siggeirsdóttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017; 28(3): 775–780.
- Söreskog E, Ström O, Spångéus A, et al. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone. 2020; 134: 115286.
- Wong RM, Wong PY, Liu C, et al. The imminent risk of a fracture-existing worldwide data: a systematic review and meta-analysis. Osteoporos Int. 2022; 33(12): 2453–2466.
- Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007; 297(4): 387–394.
- Giangregorio LM, Leslie WD. Manitoba Bone Density Program. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res. 2010; 25(6): 1400–1405.
- Nymark T, Lauritsen JM, Ovesen O, et al. Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int. 2006; 17(9): 1353–1357.
- van Geel TA, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009; 68(1): 99–102.
- Silva BC, Madeira M, d'Alva CB, et al. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO). Arch Endocrinol Metab. 2022; 66(5): 591–603.
- Toth E, Banefelt J, Åkesson K, et al. History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture. J Bone Miner Res. 2020; 35(5): 861–868.
- Adachi JD, Brown JP, Schemitsch E, et al. Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. BMC Musculoskelet Disord. 2021; 22(1): 224.
- Balasubramanian A, Zhang J, Chen L, et al. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2019; 30(1): 79–92.
- Nowakowska-Płaza A, Zielińska E, et al. Identyfikacja osób zagrożonych złamaniami osteoporotycznymi jest łatwa, szybka i skuteczna – mamy na to dowody. Prakt Ortop Traumat. 2023; 4: 8–18.
- Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji: Program profilaktyki osteoporozy — omówienie. https://youtu.be/rNRgQD2uaD0.
- McCloskey E, Rathi J, Heijmans S, et al. The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int. 2021; 32(2): 251–259.
- Adachi JD, Berger C, Barron R, et al. Predictors of imminent non-vertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos. 2019; 14(1): 53.
- Hannan MT, Weycker D, McLean RR, et al. Predictors of Imminent Risk of Nonvertebral Fracture in Older, High-Risk Women: The Framingham Osteoporosis Study. JBMR Plus. 2019; 3(6): e10129.
- Bonafede M, Shi N, Barron R, et al. Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos. 2016; 11(1): 26.
- Ramchand SK, David NL, Leder BZ, et al. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. J Clin Densitom. 2016; 19(3): 346–351.
- Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018; 103(8): 2949–2957.
- Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022; 33(6): 1243–1256.
- Cosman F, Nieves JW, Dempster DW. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. J Bone Miner Res. 2017; 32(2): 198–202.
